Evidence map›Paper›PMID 38306303›Full record

ArticleACS biomaterials science & engineering2024

Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer.

Mackenzie A Scully, Ruth Wilhelm, Dana E Wilkins, Emily S Day

Open access · greenAbstract read
In one paragraph

Article in ACS biomaterials science & engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Membrane-modified lipid nanoparticles for RNA delivery.Molecular therapy. Methods & clinical development · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mackenzie A ScullyDepartment of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.ORCID 0000-0001-6443-4287
Ruth WilhelmDepartment of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.
Dana E WilkinsDepartment of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.
Emily S DayDepartment of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States of America.ORCID 0000-0002-8707-826X
University of Delaware · US

Funding

Understanding synovial macrophage inflamm-aging within osteoarthritisP20GM139760 · NIGMS · UNIVERSITY OF DELAWARE · PI DAWN M ELLIOTT · 2021 to 2026
$19.1M
Multifunctional siRNA/antibody nanocarriers to treat metastatic triple-negative breast cancerR01CA211925 · NCI · UNIVERSITY OF DELAWARE · PI DAY, EMILY S · 2019 to 2023
$1.7M
NCI NIH HHS R01 CA211925NIGMS NIH HHS P20 GM139760
6 · The paper itself

Abstract

There is an outstanding need for targeted therapies for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype. Since TNBC's rapid growth and metastasis are driven by hyperactive Wnt signaling, suppressing the key-pathway mediator β-catenin through RNA interference may improve patient outcomes. However, small interfering ribonucleic acid (siRNA) molecules require a carrier to elicit targeted gene silencing. Here, we show that 4T1 cancer cell membrane wrapped poly(lactic-

Indexed as

NanoparticlesTriple Negative Breast Neoplasmsbeta CateninCell Line, TumorHumansRNA InterferenceRNA, Small Interferingbeta CateninRNA, Small Interferingbiomimeticgene regulationmembrane-wrappednanomedicineoncologysiRNAtargeted therapyWnt signaling

Identifiers

PMID38306303
PMCPMC10939768
OpenAlexW4391469162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.